About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Stem Cell Transplantation for Newly Diagnosed M/M
Stem Cell Transplantation for Newly Diagnosed M/M
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
M
IMS 2022 on Predictors of Unsustained Negativity in MRD(-) Transplant-Eligible NDMM Pts Enrolled in the FORTE Trial
By
Mattia D'Agostino
125 views
September 14, 2022
0 Comments
Login to view comments.
Click here to Login
Stem Cell Transplantation for Newly Diagnosed M/M
18:35
Rush University Medical Center
Upfront Autologous Transplant in Multiple Myeloma
Feat.
C. Hofmeister
34:28
2022 Community Oncology Conference
Treatment Conundrums in Myeloma
Feat.
S. Giralt
04:46
ASCO 2022 Conference Coverage
ASCO 2022 on a Post Hoc Analysis of Sustained MRD Negativity From th…
Feat.
C. Rodriguez
05:24
Luciano Costa
Dara-KRd, Autologous Transplantation, and MRD Response-Adapted Conso…
07:36
ASCO 2022 Conference Coverage
ASCO 2022 on the Changing Landscape in Post-Transplant Treatment of …
Feat.
A. Jakubowiak
08:09
Krina Patel
What Constitutes a Patient That Is Newly Diagnosed With MM as Eligib…
08:41
Parameswaran Hari
The Role of Plerixafor for Stem Cell Mobilization in the Setting of …
05:09
ASCO 2022 Conference Coverage
ASCO 2022 on Myeloma Developing Regimens Using Genomics (MyDRUG) Tri…
Feat.
S. Kumar
09:32
Christian Chabannon
Stem Cell Mobilization in MM
24:19
Dana-Farber Cancer Institute
Phase 3 DETERMINATION Trial: RVd ± ASCT & Lenalidomide Maintenan…
Feat.
P. Richardson
10:29
Mary Kwok
Moving to Quadruplets in NDMM
05:37
PrecisCa
Induction Therapy for Patients With High-Risk NDMM: When to Utilize …
Feat.
A. Nooka
09:01
Mattia D'Agostino
IMS 2022 on Predictors of Unsustained Negativity in MRD(-) Transplan…
13:17
Andrzej Jakubowiak
IMS 2022 ATLAS: A Phase 3 Randomized Trial of Carfilzomib, Lenalidom…
09:09
Douglas W. Sborov
IMS 2022 Final Analysis of the GRIFFIN Trial: Daratumumab + Lenalido…
15:46
SOHO 2022 Tenth Annual Meeting
SOHO 2022: MM Frontline Therapy for Transplant-Eligible/Ineligible P…
Feat.
P. Voorhees
07:11
SOHO 2022 Tenth Annual Meeting
SOHO 2022 MM DEBATE: Auto + Maintenance Should Remain SoC in MM
Feat.
A. Krishnan
